A total of 5443 breast cancer patients with transcriptomic profile were analyzed for the clinical relevance of NRF2 expression, including cancer aggressiveness, immune cell infiltration, patient survival, and drug response. This evidence concerns the gene NFE2L2 and breast carcinoma.